$VRTX News

Last published 2d ago

2d agoJNJ VRTX HUM EW+1Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open EnrollmentPR NewswireMarket Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State...
1w agoVRTXVERTEX PHARMACEUTICALS INC / MA - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2w agoVRTXPhase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026Business Wire- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – - Data published in NEJM and presented at ASN highlight
3w agoVRTXVertex Appoints Daniel Brennan to its Board of DirectorsBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance
3w agoVRTXSickle cell gene therapies offer new hope, but access remains a major challengeCNBCFDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.
1mo agoVRTXVertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis ConferenceBusiness Wire- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children – - Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex
1mo agoVRTXFor the final 10% of cystic fibrosis, the breakthrough still hasn't comeCNBCFor the final 10% of cystic fibrosis patients who cannot benefit from breakthrough drugs, Emily's Entourage is funding research to find treatments.
1mo agoVRTXVertex to Announce Third Quarter 2026 Financial Results November 2ndBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast
1mo agoVRTXVertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE TrialBusiness Wire– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline – - In people with AMKD and type 2
1mo agoVRTXVertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute PainBusiness Wire- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the company has
2mo agoAVAI VRTX SANAReplacing Insulin Cells Works. Keeping The Cells Alive Is the TrickGlobeNewswireIssued on behalf of AVAI Bio, Inc. LAS VEGAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - Type 1 diabetes has an unusual property among serious diseases: the science of curing it is largely
2mo agoVRTX CRNXVertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamBusiness WireCrinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a
2mo agoVRTXVertex to Participate in Upcoming September Investor ConferencesBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive
3mo agoCRNX VRTXCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAnnounced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product
3mo agoVRTXVertex Reports Second Quarter 2026 Financial ResultsBusiness Wire— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development
3mo agoABCL VRTXAbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other ConditionsBusiness WireAbCellera (NASDAQ:ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune
3mo agoVRTX ELDN VKTXA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpPR Newswire(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been...
4mo agoSANA ELDN NCEL VRTXThe Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho TherapyPR NewswireUSA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the...
4mo agoVRTXVertex to Announce Second Quarter 2026 Financial Results on August 3rdBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast
4mo agoVRTX CRNXVertex to Acquire Crinetics PharmaceuticalsBusiness Wire- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only,
4mo agoVRTXVertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta ThalassemiaBusiness Wire- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional children in the U.S.
5mo agoVRTXVertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory SubmissionsBusiness Wire- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the
5mo agoVRTXVertex Presents New Data on ALYFTREK® at European Cystic Fibrosis ConferenceBusiness Wire- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex
5mo agoVRTXVertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10Business WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and Chief Executive Officer
5mo agoVRTXVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA NephropathyBusiness Wire- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted
5mo agoVRTX ALNY BEAM SANAAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumPR NewswireCell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer...
6mo agoVRTXVertex to Participate in Upcoming May Investor ConferencesBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, will participate in a fireside
6mo agoVRTXVertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in GermanyBusiness Wire-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced today that a reimbursement
6mo agoVRTXVertex Reports First Quarter 2026 Financial ResultsBusiness Wire– Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 – – Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for povetacicept in
7mo agoLCTX OCGN VRTX LGVNBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsPR NewswireFor most of modern biology, aging has been treated as a backdrop — the inevitable canvas on which individual diseases are painted. That is beginning...
7mo agoVRTXVertex to Announce First Quarter 2026 Financial Results on May 4thBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at
7mo agoVRTXVertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United StatesBusiness Wire-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the
7mo agoVRTX CRSP ALT ARWRAnti-Aging Protein Research Takes a Step Forward with Cell CloningPR NewswireEquity-Insider.com — A protein called α-Klotho circulating in the bloodstream protects the brain, heart, kidneys, and the immune system....
8mo agoVRTX VERAVertex passes key test In quest to treat kidney diseasesCNBCVertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
8mo agoVRTXVertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA NephropathyBusiness Wire- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically
8mo agoVRTXVertex to Participate in Upcoming March Investor ConferencesBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief
8mo agoVRTXVertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive ProceduresBusiness Wire-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine
8mo agoVRTXThree decades into cystic fibrosis fight, Boomer Esiason and his son Gunnar are winningCNBCAfter NFL quarterback Boomer Esiason's son was diagnosed with cystic fibrosis, it put a face on a little-known disease and marked the start of a public crusade.
8mo agoVRTXVertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3Business WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in
9mo agoVRTXVertex Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026
9mo agoVRTXWuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell EngagerPR NewswireWuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has...
9mo agoGBIO MSCLF TSX:MSCL VRTXSatellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory AffairsBusiness WireExperienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the
9mo agoVRTX FATE MNKD ARDXBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsPR NewswireThe medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for...
9mo agoARDX AVAI FATE MNKD+1Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsGlobeNewswireVANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven
9mo agoVRTXVertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12thBusiness WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference
10mo agoVRTX CRSP PRME MDGLGene Therapy: 5 Biotech Stocks Chasing the $36B PrizePR NewswireEquity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments...
10mo agoVRTXVertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12Business WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January
11mo agoAVAI CRSP NVO VRTXFrom Insulin Injections to Functional Cures: Regenerative Medicine Reshapes DiabetesGlobeNewswireVANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant
11mo agoVRTXVertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory SubmissionsBusiness Wire- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients
11mo agoVRTXVertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3Business WireVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief